

PRECEPTORSHIP PROGRAMME

Lymphoma

Malignant lymphomas
Modern classification and
management of the most
frequent entities

LUGANO
SWITZERLAND

3-4 NOVEMBER 2017

Co-Chairs Michele Ghilmini, CH
Martin Dreyling, DE

ESMO PRECEPTORSHIP PROGRAMME LYMPHOMA

Malignant lymphomas
Modern classification and management of the most frequent entities

Lugano, Switzerland
3-4 November 2017

CO-CHAIRS: Michele Ghielmini, Switzerland
Martin Dreyling, Germany

SPEAKERS: Elias Campo, Spain
Massimo Federico, Italy
Martin Hutchings, Denmark
Silvia Montoto, United Kingdom
Leticia Quintanilla-Fend, Germany
Lena Specht, Denmark

LEARNING OBJECTIVES

- To highlight the pathological bases of the most recent lymphoma classification
- To understand the role of PET in staging, re-staging and follow-up
- To review the treatment strategy for the most common lymphoma types
- To dissect the peculiarities of lymphomas arising in particular extranodal sites
- To illustrate special and innovative treatment strategies
- To discuss clinical cases between faculty and participants

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 3 November 2017

08:45-09:00 15'	Opening and welcome	
15'	Welcome from ESMO, objectives and scientific introduction	Michele Ghielmini, CH
09:00-10:40 100'	SESSION 1 Pathology and staging	
30'	The history of lymphoma classification and the 2016 WHO revision	Elias Campo, ES
20'	Methods used to diagnose lymphoma	Leticia Quintanilla-Fend, DE
20'	Role of PET in staging and treatment of lymphomas	Martin Hutchings, DK
2x15'	2 x Participant clinical case discussion	Faculty
10:40-11:10	Coffee break	
11:10-12:40 90'	SESSION 2 Indolent	
20'	Pathology of the indolent lymphoid neoplasms	Elias Campo, ES
20'	Treatment of follicular lymphoma	Michele Ghielmini, CH
20'	Treatment of chronic lymphocytic leukemia	Martin Dreyling, DE
2x15'	2 x Participant clinical case discussion	Faculty
12:40-14:00	Lunch	
14:00-15:30 90'	SESSION 3 Aggressive	
20'	Pathology of aggressive lymphomas	Leticia Quintanilla-Fend, DE
20'	Treatment of DLBCL	Michele Ghielmini, CH
20'	Lymphoma in HIV+ patients	Silvia Montoto, UK
2x15'	2 x Participant clinical case discussion	Faculty
15:30-16:00	Coffee break	
16:00-17:30 90'	SESSION 4 Mantle cell and extranodal	
20'	Management of mantle cell lymphoma	Martin Dreyling, DE
20'	MALT lymphoma	Silvia Montoto, UK
20'	CNS lymphoma	Michele Ghielmini, CH
2x15'	2 x Participant clinical case discussion	Faculty
17:30-18:00 30'	SESSION 5 Q&A session	Faculty
19:30	Dinner	

Saturday, 4 November 2017

08:30-10:00 90'	SESSION 6 Hodgkin	
20'	Treatment of early stage	Massimo Federico, IT
20'	Treatment of advanced stage	Martin Hutchings, DK
20'	Prevention and screening of long term side effects	Lena Specht, DK
2x15'	2 x Participant clinical case discussion	Faculty
10:00-10:30	Coffee break	
10:30-12:00 90'	SESSION 7 T-cell lymphomas and special treatments	
20'	New drugs for lymphoma	Martin Dreyling, DE
20'	The role of radiotherapy in lymphoma in 2017	Lena Specht, DK
20'	Systemic T-cell lymphomas	Massimo Federico, IT
2x15'	2 x Participant clinical case discussion	Faculty
12:00-12:30 30'	SESSION 8 Q&A session and closing remarks	Faculty
12:30-13:15	Lunch	

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation plus 8' Q&A / panel discussion